The neuropathology of multiple sclerosis is characterised by focal damage to white matter. However, tissue damage is also present in the cortical grey matter, with a particularly high   more »

Combination therapies in multiple sclerosis.

 

 

 The last years have seen enormous progress in our understanding of pathophysiology (1) of multiple sclerosis. In addition, the armamentarium (2) of available immunomodulatory or immunosuppressive therapies (3) has greatly increased, especially for the relapsing remitting form of the disease.

 

Since their therapeutic efficacy is often limited in individual patients, it is conceivable that combination therapies may bring improved clinical efficacy while managing increasing side effects and toxicity. The combination of agents with additive or synergistic modes of action is of particular interest. Combination of the two classes of recognised first-line treatment, a beta-interferon and glatiramer acetate is currently under evaluation in a large Phase III trial.

 

However, there are theoretical reasons for thinking that such a combination may not be particularly beneficial. None of the combination studies performed with beta-interferons to date have shown unequivocal evidence of benefit, including combinations with statins, natalizumab, and azathioprine.

 

On the other hand, for glatiramer acetate, the combination with mitoxantrone used as induction therapy may be of interest and preliminary data on combination with minocycline are also promising.

 

University of Bochum,

St. Josef-Hospital,

Dept. of Neurology,

Gudrunstr. 56, 44791,

Bochum, Germany.

 

 

Terms:

1. pathophysiology - The study of such changes.
2. Armamentarium - the equipment and materials of the clinician
3. - immunomodulatory agents that alter the immune response by suppression or enhancement

Multiple sclerosis is a lifelong, immune-mediated progressive disorder. The early age of onset and the chronic nature of the disease with accumulation of physical disability, demand a long-term ("lifelong") management, including   more »

We evaluated the safety, tolerability, pharmacodynamics, and activity of B-cell depletion with rituximab in patients with relapsing-remitting multiple sclerosis, receiving   more »

Rates of progression vary widely in primary progressive multiple sclerosis. This multicenter study aimed to identify predictors of progression over 10 years. A total of 101 patients who had been imaged at baseline and 2 years were scored on the expanded   more »

Johns Hopkins scientists have discovered to their surprise that nerves in the mammalian brain’s white matter do more than just ferry information between different brain regions, but in fact process information the way gray matter    more »

Oregon Health & Science University neuroscientist researchers, working with colleagues at the Portland Veterans Affairs Medical Center and the University of Padova in Italy, have shown that genetically inactivating a protein called cyclophilin D can protect nerve    more »

US researchers have developed regulatory T cells that are capable of suppressing multiple sclerosis and other autoimmune diseases in mice, according to a report in the March 24th Early Edition of the Proceedings of   more »